Publikationen:

(Liste unvollständig)

  • Viveiros, A., B. Schaefer, M. Panzer, B. Henninger, M. Plaikner, C. Kremser, A. Franke, S. Franzenburg, M. P. Hoeppner, R. Stauder, A. Janecke, H. Tilg and H. Zoller (2021). „MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes.“ Hepatology.
  • Schaefer, B., H. Zoller and M. Wolf (2021). „Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose.“ J Clin Endocrinol Metab.
  • Schaefer, B., M. Tobiasch, A. Viveiros, H. Tilg, N. A. Kennedy, M. Wolf and H. Zoller (2021). „Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.“ Br J Clin Pharmacol 87(5): 2256-2273.
  • Grander, C., B. Schaefer, J. Schwarzler, F. Grabherr, D. M. de Graaf, B. Enrich, G. Oberhuber, L. Mayr, M. Sangineto, N. Jaschke, T. E. Adolph, M. Effenberger, A. R. Moschen, C. A. Dinarello, H. Zoller and H. Tilg (2021). „Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans.“ Gut 70(3): 585-594.
  • Viveiros, A., M. Panzer, N. Baumgartner, B. Schaefer, A. Finkenstedt, B. Henninger, I. Theurl, K. Nachbaur, G. Weiss, R. Haubner, C. Decristoforo, H. Tilg and H. Zoller (2020). „Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.“ Liver Int 40(8): 1941-1951.
  • Viveiros, A., V. Beliveau, M. Panzer, B. Schaefer, B. Glodny, B. Henninger, H. Tilg, H. Zoller and C. Scherfler (2020). „Neurodegeneration in Hepatic and Neurologic Wilson’s Disease.“ Hepatology.
  • Schaefer, B., E. Meindl, S. Wagner, H. Tilg and H. Zoller (2020). „Intravenous iron supplementation therapy.“ Mol Aspects Med 75: 100862.
  • Viveiros, A., B. Schaefer, H. Tilg and H. Zoller (2019). „Iron Matryoshka-Haemochromatosis nested in Ferroportin Disease?“ Liver Int 39(6): 1014-1015.
  • Viveiros, A., A. Finkenstedt, B. Schaefer, M. Mandorfer, B. Scheiner, K. Lehner, M. Tobiasch, T. Reiberger, H. Tilg, M. Edlinger and H. Zoller (2018). „Transferrin as a predictor of survival in cirrhosis.“ Liver Transpl 24(3): 343-351.
  • Schaefer, B., H. Zoller and S. Schneeberger (2018). „Con: Liver transplantation for expanded criteria malignant diseases.“ Liver Transpl 24(1): 104-111.
  • Schaefer, B., A. Viveiros, R. Al-Zoairy, S. Blach, S. Brandon, H. Razavi, L. Dorn, A. Finkenstedt, M. Effenberger, I. Graziadei, M. Sarcletti, H. Tilg and H. Zoller (2018). „Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030.“ PLoS One 13(7): e0200750.
  • Schaefer, B., M. Mandorfer, A. Viveiros, A. Finkenstedt, P. Ferenci, S. Schneeberger, H. Tilg and H. Zoller (2018). „Heterozygosity for the alpha-1-antitrypsin Z allele in cirrhosis is associated with more advanced disease.“ Liver Transpl 24(6): 744-751.
  • Viveiros, A., B. Schaefer, H. Tilg and H. Zoller (2019). „Iron Matryoshka-Haemochromatosis nested in Ferroportin Disease?“ Liver Int 39(6): 1014-1015.
  • Zoller, H., B. Schaefer and B. Glodny (2017). „Iron-induced hypophosphatemia: an emerging complication.“ Curr Opin Nephrol Hypertens 26(4): 266-275.
  • Viveiros, A., M. Reiterer, B. Schaefer, A. Finkenstedt, S. Schneeberger, H. Schwaighofer, P. Moser, R. Sprenger, B. Glodny, W. Vogel, A. R. Janecke and H. Zoller (2017). „CCBE1 mutation causing sclerosing cholangitis: Expanding the spectrum of lymphedema-cholestasis syndrome.“ Hepatology 66(1): 286-288.
  • Viveiros, A., R. Rehwald, E. Vettori, A. Finkenstedt, M. Effenberger, B. Schaefer, L. Dorn, H. Tilg, S. Schneeberger, B. Glodny, H. Zoller and M. C. Freund (2017). „Prognostic significance of hepatic arterial collaterals in liver transplant recipients with biliary strictures.“ Clin Transplant 31(2).
  • Schaefer, B., P. Wurtinger, A. Finkenstedt, V. Braithwaite, A. Viveiros, M. Effenberger, I. Sulzbacher, A. Moschen, A. Griesmacher, H. Tilg, W. Vogel and H. Zoller (2016). „Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.“ PLoS One 11(12): e0167146.
  • Finkenstedt, A., A. Vikoler, M. Portenkirchner, K. Mulleder, M. Maglione, C. Margreiter, P. Moser, W. Vogel, R. Bale, M. Freund, A. Luger, H. Tilg, J. Petersen, S. Schneeberger, I. Graziadei, H. Zoller and B. Glodny (2016). „Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy.“ Liver Int 36(5): 688-695.
  • Schaefer B, Haschka D, Finkenstedt A, et al. Impaired hepcidin expression in alpha-1-antitrypsin deficiency associated with iron overload and progressive liver disease. Hum Mol Genet 2015;24:6254-63.
  • Zoller, H., & Finkenstedt, A. (2014). Should C282Y homozygotes with mild iron overload be treated? J Hepatol. doi: 10.1016/j.jhep.2014.11.037
  • Schaefer, B., Steurer, M., Glodny, B., Neureiter, D., Moser, P., Dorn, L., Vogel, W., & Zoller, H. (2014). First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: complete remission followed by lethal sepsis. Liver Transpl, 20(9), 1145-1148. doi: 10.1002/lt.23918
  • Schaefer, B., Effenberger, M., & Zoller, H. (2014). Iron metabolism in transplantation. Transpl Int, 27(11), 1109-1117. doi: 10.1111/tri.12374
  • Praschberger, R., Schranz, M., Griffiths, W. J., Baumgartner, N., Hermann, M., Lomas, D. J., Pietrangelo, A., Cox, T. M., Vogel, W., & Zoller, H. (2014). Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor. Biochim Biophys Acta, 1842(9), 1406-1412. doi: 10.1016/j.bbadis.2014.05.011
  • Finkenstedt, A., Schranz, M., Bosch, S., Karall, D., Burgi, S. S., Ensinger, C., Drach, M., Mayr, J. A., Janecke, A. R., Vogel, W., Nachbaur, D., & Zoller, H. (2013). MNGIE Syndrome: Liver Cirrhosis Should Be Ruled Out Prior to Bone Marrow Transplantation. JIMD Rep, 10, 41-44. doi: 10.1007/8904_2012_199
  • Finkenstedt, A., Nachbaur, K., Zoller, H., Joannidis, M., Pratschke, J., Graziadei, I. W., & Vogel, W. (2013). Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. Liver Transpl, 19(8), 879-886. doi: 10.1002/lt.23678
  • Finkenstedt, A., Auer, C., Glodny, B., Posch, U., Steitzer, H., Lanzer, G., Pratschke, J., Biebl, M., Steurer, M., Graziadei, I., Vogel, W., & Zoller, H. (2013). Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol, 11(12), 1667-1672. doi: 10.1016/j.cgh.2013.06.025
  • Zoller, H., Schloegl, A., Schroecksnadel, S., Vogel, W., & Fuchs, D. (2012). Interferon-alpha therapy in patients with hepatitis C virus infection increases plasma phenylalanine and the phenylalanine to tyrosine ratio. J Interferon Cytokine Res, 32(5), 216-220. doi: 10.1089/jir.2011.0093
  • Zoller, H., & Knisely, A. S. (2012). Control of iron metabolism–lessons from neonatal hemochromatosis. J Hepatol, 56(6), 1226-1229. doi: 10.1016/j.jhep.2012.02.012
  • Finkenstedt, A., Widschwendter, A., Brasse-Lagnel, C. G., Theurl, I., Hubalek, M., Dieplinger, H., Tselepis, C., Ward, D. G., Vogel, W., & Zoller, H. (2012). Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells Mol Dis, 48(4), 233-237. doi: 10.1016/j.bcmd.2012.02.001
  • Finkenstedt, A., Dorn, L., Edlinger, M., Prokop, W., Risch, L., Griesmacher, A., Graziadei, I., Vogel, W., & Zoller, H. (2012). Cystatin C is a strong predictor of survival in patients with cirrhosis: is a cystatin C-based MELD better? Liver Int, 32(8), 1211-1216. doi: 10.1111/j.1478-3231.2012.02766.x
  • Dorn, L., Finkenstedt, A., Schranz, M., Prokop, W., Griesmacher, A., Vogel, W., & Zoller, H. (2012). Immunoglobulin subclass 4 for the diagnosis of immunoglobulin subclass 4-associated diseases in an unselected liver and pancreas clinic population. HPB (Oxford), 14(2), 122-125. doi: 10.1111/j.1477-2574.2011.00413.x
  • Mayr, R., Griffiths, W. J., Hermann, M., McFarlane, I., Halsall, D. J., Finkenstedt, A., Douds, A., Davies, S. E., Janecke, A. R., Vogel, W., Cox, T. M., & Zoller, H. (2011). Identification of mutations in SLC40A1 that affect ferroportin function and phenotype of human ferroportin iron overload. Gastroenterology, 140(7), 2056-2063, 2063 e2051. doi: 10.1053/j.gastro.2011.02.064
  • Mayr, R., Janecke, A. R., Schranz, M., Griffiths, W. J., Vogel, W., Pietrangelo, A., & Zoller, H. (2010). Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol, 53(5), 941-949. doi: 10.1016/j.jhep.2010.05.016
  • Krismer, F., Roos, J. C., Schranz, M., Graziadei, I. W., Mechtcheriakov, S., Vogel, W., Carpenter, R. H., & Zoller, H. (2010). Saccadic latency in hepatic encephalopathy: a pilot study. Metab Brain Dis, 25(3), 285-295. doi: 10.1007/s11011-010-9210-1
  • Finkenstedt, A., Wolf, E., Hofner, E., Gasser, B. I., Bosch, S., Bakry, R., Creus, M., Kremser, C., Schocke, M., Theurl, M., Moser, P., Schranz, M., Bonn, G., Poewe, W., Vogel, W., Janecke, A. R., & Zoller, H. (2010). Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol, 53(6), 1101-1107. doi: 10.1016/j.jhep.2010.04.039
  • Schranz, M., Talasz, H., Graziadei, I., Winder, T., Sergi, C., Bogner, K., Vogel, W., & Zoller, H. (2009). Diagnosis of hepatic iron overload: a family study illustrating pitfalls in diagnosing hemochromatosis. Diagn Mol Pathol, 18(1), 53-60. doi: 10.1097/PDM.0b013e31817cfd4b
  • Schranz, M., Bakry, R., Creus, M., Bonn, G., Vogel, W., & Zoller, H. (2009). Activation and inactivation of the iron hormone hepcidin: Biochemical characterization of prohepcidin cleavage and sequential degradation to N-terminally truncated hepcidin isoforms. Blood Cells Mol Dis, 43(2), 169-179. doi: 10.1016/j.bcmd.2009.03.008
  • Finkenstedt, A., Bianchi, P., Theurl, I., Vogel, W., Witcher, D. R., Wroblewski, V. J., Murphy, A. T., Zanella, A., & Zoller, H. (2009). Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol, 144(5), 789-793. doi: 10.1111/j.1365-2141.2008.07535.x